Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals Inc.

In a report released today, Jason Gabelman from TD Cowen maintained a Hold rating on HF Sinclair Corporation, with a price target of $53.00. Accord...

TD Cowen Reaffirms Their Hold Rating on HF Sinclair Corporation (DINO)

Gaucho Group Holdings ( ($VINO) ) has issued an announcement. On December 1, 2025, Gaucho Group Holdings provided an update to its stockholders con...

Gaucho Group Holdings Updates on Argentina Economic Situation

Virgin Wines UK PLC ( ($GB:VINO) ) has issued an update. Virgin Wines UK PLC announced that as of November 30, 2025, its issued share capital consi...

Virgin Wines Updates Share Capital and Voting Rights Information

Hino Motors ( ($JP:7205) ) has provided an announcement. Hino Motors has announced the execution of an agreement to transfer its Hamura Plant to To...

Hino Motors to Transfer Hamura Plant to Toyota

Nikon Corp ( ($NINOF) ) has released its Q2 earnings. Here is a breakdown of the information Nikon Corp presented to its investors. Nikon Corporati...

Nikon Corp Reports Mixed Earnings Amid Market Challenges

Nikon Corporation ( ($NINOY) ) has released its Q2 earnings. Here is a breakdown of the information Nikon Corporation presented to its investors. N...

Nikon Corporation Reports Mixed Financial Results

Virgin Wines UK PLC ( ($GB:VINO) ) has shared an announcement. Virgin Wines UK PLC has announced the posting of its Annual Report & Accounts for th...

Virgin Wines UK PLC Releases Annual Report for 2025

Virgin Wines UK PLC ( ($GB:VINO) ) has shared an announcement. Virgin Wines UK PLC has announced its upcoming Annual General Meeting and General Me...

Virgin Wines UK PLC Seeks Approval for Share Buyback and Rule 9 Waiver

Barclays analyst Theresa Chen maintained a Hold rating on HF Sinclair Corporation today and set a price target of $54.00. Chen covers the Energy se...

HF Sinclair Corporation (DINO) Gets a Hold from Barclays

The recent pullback in tech has rattled nerves, but so far it looks more like a dip than a meaningful setback. The NASDAQ is only 4.5% off its late...

Current Quarter	$-0.37	Next Quarter	$-0.34
Current Year	$-1.98	Next Year	$-1.24
QoQ Growth	+8.1%	YoY Growth	+37.4%
3Y EPS CAGR	+39.0%	Target Price	$7.63
Consensus	Buy	Upside	+270.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INO	$2.06	-3.29%	745.21K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INO	$2.06	-3.3%	745.21K
3
4
5
6

INO

INO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Inovio Pharmaceuticals Inc. Data in Excel

Get Inovio Pharmaceuticals Inc. Data in Excel